Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Cantor Fitzgerald
Dow
Argus Health
QuintilesIMS
Julphar
Fish and Richardson
Fuji
Deloitte
Mallinckrodt

Generated: February 20, 2018

DrugPatentWatch Database Preview

XTORO Drug Profile

« Back to Dashboard

When do Xtoro patents expire, and when can generic versions of Xtoro launch?

Xtoro is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-four patent family members in seventeen countries.

The generic ingredient in XTORO is finafloxacin. Additional details are available on the finafloxacin profile page.
Summary for XTORO
International Patents:34
US Patents:3
Applicants:1
NDAs:1
Bulk Api Vendors: 15
Patent Applications: 8
Drug Prices:see details
DailyMed Link:XTORO at DailyMed
Drug patent expirations by year for XTORO

US Patents and Regulatory Information for XTORO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for XTORO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for XTORO

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Covington
McKinsey
Cipla
Julphar
Fuji
US Army
Argus Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot